Education
About Us
Working with TipRanks
Follow Us
InspireMD Inc (NSPR)
:NSPR
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.22Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: -7.69%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments and challenges. While there was growth in CGuard revenue and significant progress in clinical trials and commercial preparations, the company faced increased operating expenses and a higher net loss. The anticipated delay in FDA approval also presents a challenge. However, the potential U.S. market opportunity and strategic progress provide optimism.Company Guidance
In the first quarter of fiscal year 2025, InspireMD reported CGuard revenue of $1.53 million, marking a 1.2% year-over-year growth with 2,611 units sold, contributing to a total of approximately 64,000 implants sold to date. The company remains optimistic for the FDA approval of CGuard Prime in Q3 2025, which could potentially generate $12 million in U.S. revenue based on current market average selling prices (ASPs). Operating expenses increased by 52.5% to $11.75 million due to U.S. sales force expansion and preparation for the CGuard Prime launch. The net loss for the quarter was $11.17 million, with cash and cash equivalents totaling $26.09 million as of March 31, 2025. InspireMD is also advancing its clinical pipeline with strong progress in the C-GUARDIANS II pivotal study, anticipating first-half 2026 approval, and is preparing for the U.S. launch with a team of approximately 20 sales and marketing professionals.CGuard Revenue Growth
CGuard revenue reached $1.53 million, reflecting a 1.2% growth year-over-year with 2,611 stents sold.
U.S. Market Opportunity
Potential revenue of $12 million in the U.S. market for CGuard Prime based on current international sales volumes.
Clinical Pipeline Progress
Strong enrollment in C-GUARDIANS II study and first patients enrolled in Tandem Lesion Early Feasibility Study.
Commercial Launch Preparations
Onboarding of 20 sales and marketing professionals and establishment of a facility in Miami for U.S. operations.
NSPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NSPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $2.60 | $2.60 | 0.00% |
Mar 12, 2025 | $2.79 | $2.81 | +0.72% |
Nov 12, 2024 | $2.46 | $2.38 | -3.25% |
Aug 06, 2024 | $2.96 | $2.98 | +0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does InspireMD Inc (NSPR) report earnings?
InspireMD Inc (NSPR) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is InspireMD Inc (NSPR) earnings time?
InspireMD Inc (NSPR) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NSPR EPS forecast?
NSPR EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.